Clinical Trial Update: A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study of DMOT4039A in participants with unresectable pancreatic cancer or platinum-resistant ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Pancreatic Cancer

Drugs mentioned

• DMOT4039A

Snippet

Sponsor: Genentech, Inc. | Conditions: Ovarian Cancer | Phase 1 | Status: COMPLETED